|
|
|
Insider
Information: |
Column Group Ii Gp, Lp |
Relationship: |
10% Owner |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
800,000 |
|
Indirect Shares
|
1,000 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$1,540 |
|
|
Total
Shares |
801,000 |
|
|
Total
Value |
$1,540 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
59
|
0
|
Stock
price went up :
|
24
|
0
|
Stock
price went down : |
35
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-3.1%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
800,000 |
|
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
78 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-10-17 |
4 |
B |
$10.62 |
$72,407 |
D/D |
6,818 |
162,990 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-11-04 |
4 |
B |
$11.99 |
$100,824 |
D/D |
8,409 |
253,907 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-03-05 |
4 |
B |
$18.00 |
$149,526 |
D/D |
8,307 |
445,444 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2022-11-04 |
4 |
B |
$4.72 |
$165,320 |
I/I |
35,058 |
339,845 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-03-04 |
4 |
B |
$17.96 |
$179,349 |
D/D |
9,986 |
437,137 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2022-11-21 |
4 |
B |
$5.00 |
$179,942 |
I/I |
35,997 |
375,842 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
D/D |
14,587 |
1,303,741 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-04-02 |
4 |
B |
$12.40 |
$184,140 |
D/D |
14,850 |
1,289,154 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2023-01-19 |
4 |
B |
$5.00 |
$188,105 |
I/I |
37,639 |
732,559 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-10-25 |
4 |
B |
$4.75 |
$242,387 |
I/I |
51,046 |
51,046 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-03-02 |
4 |
B |
$17.90 |
$252,820 |
D/D |
14,124 |
388,393 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-05-20 |
4 |
B |
$13.48 |
$256,533 |
I/I |
19,034 |
48,987 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-05-19 |
4 |
B |
$13.25 |
$273,922 |
I/I |
20,666 |
48,359 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-10-15 |
4 |
B |
$10.31 |
$342,292 |
D/D |
33,200 |
121,272 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-10-26 |
4 |
B |
$4.85 |
$353,041 |
I/I |
72,774 |
123,820 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-05-10 |
4 |
B |
$11.36 |
$355,283 |
I/I |
31,265 |
31,818 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-10-16 |
4 |
B |
$10.26 |
$358,074 |
D/D |
34,900 |
156,172 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-10-14 |
4 |
B |
$10.36 |
$361,564 |
D/D |
34,900 |
88,072 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2022-10-27 |
4 |
B |
$4.86 |
$373,638 |
I/I |
76,877 |
200,697 |
1.5 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2019-10-18 |
4 |
B |
$11.29 |
$392,000 |
D/D |
34,721 |
197,711 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2022-05-16 |
4 |
B |
$12.90 |
$427,891 |
I/I |
33,166 |
42,671 |
1.5 |
% |
|
78 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|